H. Yimer

发表

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib

D. Cherepanov, S. Kambhampati, R. Rifkin, 2020, Clinical Lymphoma Myeloma and Leukemia.

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.

S. Jagannath, S. Lonial, A. Oriol, 2019, The Lancet. Haematology.

Rivaroxaban for Thromboprophylaxis in High‐Risk Ambulatory Patients with Cancer

A. Khorana, G. Lyman, J. Eikelboom, 2019, The New England journal of medicine.

Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)

A. Khorana, G. Lyman, J. Eikelboom, 2018, Blood.

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study

J. Burke, R. Rifkin, M. Qi, 2019, British journal of haematology.

Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options

E. Hubbell, Minetta C. Liu, G. Chung, 2022, Tumori.

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial

P. Ganly, S. O'brien, C. Tam, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.

J. Burke, I. Flinn, A. Idoine, 2022, The Lancet. Haematology.

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.

P. Ganly, S. O'brien, C. Tam, 2022, The New England journal of medicine.

Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

G. Acton, M. Davids, S. O'brien, 2021, Haematologica.

Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib.

J. Burke, I. Flinn, T. Guthrie, 2021, Journal of Clinical Oncology.

Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib

J. Burke, I. Flinn, J. Cultrera, 2020, Blood.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia

J. Burke, A. Danilov, M. Boxer, 2020, Leukemia & lymphoma.

Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine.

J. Burke, P. Trask, A. Danilov, 2021, Clinical lymphoma, myeloma & leukemia.

Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States

A. Cohen, M. Coleman, C. Farber, 2023, EJHaem.

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study

J. Burke, R. Rifkin, M. Qi, 2022, Leukemia & lymphoma.

CheckMate 8KX: Phase 1/2 multitumor preliminary analyses of a subcutaneous formulation of nivolumab (± rHuPH20).

S. Dolfi, H. Vezina, I. Lugowska, 2021 .

Performance of a targeted methylation-based multi-cancer early detection test by race and ethnicity.

E. Hubbell, C. Swanton, L. Roberts, 2021, Preventive medicine.

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib

D. Cherepanov, S. Kambhampati, R. Rifkin, 2020, Clinical Lymphoma Myeloma and Leukemia.

Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).

J. Vose, K. Kolibaba, B. Cheson, 2019, Journal of Clinical Oncology.

Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

P. Ganly, S. O'brien, C. Tam, 2022, Blood.

Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).

J. Burke, R. Advani, K. Kolibaba, 2015 .

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

Xiwen Ma, Seung Tae Lee, M. Leiba, 2021, Blood.

A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185.

Jason J. Z. Liao, S. Jagannath, S. Lonial, 2018 .

Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)

J. Burke, R. Rifkin, M. Qi, 2018, Blood.

Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies

J. Burke, I. Flinn, T. Guthrie, 2021, Blood.

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Preliminary Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)

J. Burke, I. Flinn, J. Friedman, 2021, Blood.

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)

J. Burke, I. Flinn, J. Friedman, 2022, Blood.

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

D. Berry, S. Cummings, E. Fung, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

J. Burke, R. Rifkin, M. Qi, 2019, Blood.

P1160: RESULTS OF A PHASE 2 EXPANDED ACCESS STUDY OF ZANUBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA

A. Cohen, C. Farber, H. Yimer, 2022, HemaSphere.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS)

T. Kadia, Dajun Yang, Y. Zhai, 2022, Blood.

Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)

Scott E. Smith, J. Burke, R. Advani, 2016 .

A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia

E. R. Broun, B. Anz, W. Donnellan, 2024, Hematological oncology.